Tranexamic Acid During Colonic Endoscopic Resection Procedures
Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding
Assaf-Harofeh Medical Center
200 participants
May 1, 2022
INTERVENTIONAL
Conditions
Summary
Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.
Eligibility
Inclusion Criteria2
- Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.
- Age \> 18 years
Exclusion Criteria3
- patients with histories of allergic reactions to TXA
- history of seizures
- pregnancy
Interventions
Injection of standard solution
Submucosal injection of standard solution including TXA during EMR procedure
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05345613